ReviewJournal of child neurology2008
Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.
Review in Journal of child neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma.Journal of neuro-oncology · 2010Trial
- Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Current treatment of optic nerve gliomas.Current opinion in ophthalmology · 2019Review
- Review of low-grade gliomas in children--evolving molecular era and therapeutic insights.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015Review
- Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.Paediatric drugs · 2013Review
- Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosis.The Journal of biological chemistry · 2012Article
- Are patients with encephalocraniocutaneous lipomatosis at increased risk of developing low-grade gliomas?Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA.Journal of neuro-oncology · 2010Article
- Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis.Journal of neuro-oncology · 2010Article
- Pediatric low-grade gliomas.Journal of child neurology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Relatively little is known about the seminal genetic events that trigger the development of low-grade gliomas in children. Genetically engineered mouse models of the neurofibromatosis-1-inherited tumor predisposition syndrome have identified key intracellular growth control pathways, defined the contribution of the tumor microenvironment to glioma growth, and helped researchers understand the genetic basis for glioma susceptibility. In addition, genetically engineered mouse low-grade glioma models have recently been used in preclinical therapeutic studies to evaluate the efficacy of particular biologically based therapies and to define outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.